Higher fixed costs and margin pressures in key segments temper near-term profitability improvements for Saab AB. Read why ...
ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
As dusk falls over Lagos, worshipers in their numbers gathered across worship centres to welcome the New Year - something ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback